Clinical Focus

  • Pediatric Hematology-Oncology

Academic Appointments

Professional Education

  • Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (2023)
  • Fellowship: Baylor College of Medicine (2021) TX
  • Board Certification: American Board of Pediatrics, Pediatrics (2017)
  • Residency: Stanford School of Medicine (2017) CA
  • Medical Education: University of Texas Southwestern Medical Center (2014) TX

Contact

  • Academic
    University - Academic staff Department: Pediatrics - Hematology/Oncology Position: Clinical Assistant Professor
  • Clinical (Primary)  Pediatric Hematology and Oncology 725 Welch Rd MC 5913 Palo Alto, CA 94304 (650) 497-8101 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5798

All Publications

  • Prophylactic penicillin after 5 years of age in patients with sickle cell disease: A survey of sickle cell disease experts PEDIATRIC BLOOD & CANCER McCavit, T. L., Gilbert, M., Buchanan, G. R. 2013; 60 (6): 935-939

    Abstract

    Since the publication of the Prophlyactic Penicillin Study II in 1995, the management of penicillin prophylaxis for children with sickle cell disease (SCD) after 5 years of age has been controversial. In this study, we sought to describe current practice patterns of pediatric hematologists related to cessation of penicillin prophylaxis for children with SCD after 5 years of age.We performed a cross-sectional, electronic survey of pediatric hematologists with expertise in SCD to examine practices regarding penicillin prophylaxis in children with SCD after 5 years of age. We also investigated factors potentially associated with continuation of penicillin prophylaxis using the Jonckheere-Terpstra test and Fisher's exact test.Of the 106 physicians surveyed from 76 centers, 84% completed the survey. Among respondents, 76% routinely recommended cessation of penicillin prophylaxis after 5 years of age. The practice of routinely continuing penicillin after 5 years of age was associated with decreased concern about antibiotic resistance in Streptococcus pneumoniae (P = 0.01), with the usage of prophylactic penicillin in mild SCD genotypes (sickle hemoglobin-C disease and sickle β(+) thalassemia, P = <0.001), and with increasing use of other preventive evaluations (e.g., MRI for silent stroke) in childhood (P = 0.05).Most pediatric hematologists with an SCD expertise recommend cessation of prophylactic penicillin after 5 years of age.

    View details for DOI 10.1002/pbc.24395

    View details for Web of Science ID 000317934800017

    View details for PubMedID 23193095

  • PROPHYLACTIC PENICILLIN FOR CHILDREN WITH SICKLE CELL ANEMIA OVER 5 YEARS OF AGE: A NATIONAL SURVEY Gilbert, M., McCavit, T., Buchanan, G. WILEY-BLACKWELL. 2012: 1073–73

    View details for Web of Science ID 000302864200204

  • DOES CONTINUATION OF PROPHYLACTIC PENICILLIN BEYOND AGE 5 PREVENT INVASIVE PNEUOMOCOCCAL DISEASE IN CHILDREN WITH SICKLE CELL ANEMIA? Gilbert, M., McCavit, T., Buchanan, G. WILEY-BLACKWELL. 2012: 1015–15

    View details for Web of Science ID 000302864200007